Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.61 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.61 |
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Substance P SCHEMBL1116347 | 0.97 | OPRD1 (0.67) | OPRD1F2NMUR2NMUR1 | |
| Substance P SCHEMBL18769078 | 0.97 | OPRD1 (0.67) | OPRD1F2NMUR2NMUR1 | |
| Substance P SCHEMBL29831869 | 0.97 | OPRD1 (0.67) | OPRD1F2NMUR2NMUR1 | |
| Substance P SCHEMBL17887651 | 0.97 | OPRD1 (0.67) | OPRD1F2NMUR2NMUR1 | |
| Substance P SCHEMBL19057679 | 0.97 | OPRD1 (0.67) | OPRD1F2NMUR2NMUR1 | |
| SCHEMBL31332027 | 0.94 | OPRD1 (0.71) | OPRD1NMUR2NMUR1 | |
| SCHEMBL30342262 | 0.94 | OPRD1 (0.71) | OPRD1NMUR2NMUR1 | |
| SCHEMBL29369748 | 0.93 | OPRD1 (0.59) | OPRD1F2NMUR2NMUR1APLNR | |
| SCHEMBL31135242 | 0.91 | F2 (0.58) | OPRD1F2NMUR2NMUR1APLNR | |
| SCHEMBL29498256 | 0.90 | OPRD1 (0.67) | OPRD1F2NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680966-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2026-01-21 | — | — | EP | disclosed |
| CN-119219738-A | Alternaria sinica antihypertensive peptide as well as preparation method and application thereof | 湘潭大学 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024194276-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2024-09-26 | — | — | WO | disclosed |
| CN-118272410-A | Preparation method of spy catcher mutant and application of spy catcher mutant in fluorescent protein model system | 江苏贝奥泰克生物科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230149516-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230097988-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-03-30 | — | — | US | disclosed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-4111201-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | disclosed |
| CN-115280148-A | Method for determining peptidylglycine alpha-amidating monooxygenase (PAM) and use thereof for diagnostic purposes | PAM治疗诊断有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115243709-A | Use of peptidylglycine alpha-amidating monooxygenase (PAM) for therapeutic purposes | PAM治疗诊断有限公司 | 2022-10-25 | — | — | CN | disclosed |